1. Home
  2. ITRM

ITRM

Iterum Therapeutics plc

Logo Iterum Therapeutics plc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-15-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Founded: 2015 Country:
Ireland
Ireland
Employees: N/A City: DUBLIN 2
Market Cap: 28.9M IPO Year: 2018
Target Price: $6.00 AVG Volume (30 days): 622.1K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.96 EPS Growth: N/A
52 Week Low/High: $0.62 - $2.50 Next Earning Date: 05-10-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: